Modified Release Formulation Development

Optimize your modified-release formulations.

Get expert support for your modified-release programs.

Your challenges. Our solutions.

Learn more about our expertise in modified release.

Modified Release, Formulation Development, Translational Pharmaceutics

Alternative Strategies for Development of Modified Release Dosage Forms

More about our modified release capabilities

Browse More

Scientific Poster, Translational Pharmaceutics

CRS 2023: Development of a Multi-Pill Abuse Resistant (MPAR®) Multiparticulate Modified Release Formulation to Prevent Opioid Overdose

14 August 2023

Download Now

On-Demand Webinar, Modified Release, Commercial Manufacturing, Formulation Development

Non-Clinical vs Clinical: Risks & Considerations When Developing Modified Release Dosage Forms

1 September 2022

Watch Now

Scientific Poster, Modified Release, Formulation Development

Development of modified release matrix tablet formulation using solid lipid Compritol 888 for a poorly water soluble drug

22 December 2021

Download Now

Whitepaper, Modified Release, Formulation Development, Translational Pharmaceutics

Alternative Strategies for Development of Modified Release Dosage Forms

Download Now

Browse More

Meet our team of modified release experts

We help turn your molecules into medicines of the future, working as partners with a single goal of getting get new treatments to those in need, fast. Meet some of our team members that you'll work with when you have a project with us.

Dr. Andrew Lewis

Chief Scientific Officer

Dr. Andrew (Andy) Lewis is the Chief Scientific Officer at Quotient Sciences. As the leader of Quotient Sciences' scientific teams...

About Andrew

Dr. Vanessa Zann

Executive Drug Development Consultant

Dr. Vanessa Zann is an Executive Drug Development Consultant at Quotient Sciences, with over twenty-five years industry experience...

About Vanessa

Dr. Asma Patel

VP, Integrated Development Services

Dr. Asma Patel is VP of Integrated Development Services at Quotient Sciences. In this role, Asma is responsible for providing scie...

About Asma

What are the different modified-release formats that Quotient Sciences works with?

Modified-release format	Objective	Formulation technology
Gastro-retention	Keep the formulation in the stomach for an extended period to maximize the duration of absorption or therapeutic activity	Swellable tablets (monolithic, bilayer, trilayer)
Gastro-resistant	Prevent release of the drug in the stomach and/or upper gastrointestinal (GI) tract Overcome first-pass metabolism or gastric irritation	Enteric-coated tablets or capsules
Sustained or extended release	Extend the in-vivo release profile of the drug or enable once-daily dosing	Matrix tablets, coated tablets, or multiparticulates
Targeted or controlled delivery	Release the drug at or near the intended site of absorption or action Have either immediate-release or extended-release characteristics Deliver time-, pH-, or microbially-triggered release	Tablets, capsules, or multiparticulates
Biphasic release	Eliminate the need for repeat dosing Provide rapid therapeutic effect from an immediate-release layer and extended dosing from a sustained-release layer	Bilayer tablets or multiparticulates
Pulsatile release	Release the drug as a pulse after a pre-determined lag time, designed according to the body’s circadian rhythm Provide a release mechanism beneficial for drugs where time-dependent dosing is required or those that undergo first-pass metabolism	Bilayer tablets or multiparticulates

Go further with Quotient Sciences

Case Studies

Discover how we've helped pharma and biotech organizations successfully meet their milestones.

See Examples

Translational Pharmaceutics®

Accelerates drug development by integrating real-time cGMP manufacturing and clinical activities.

Explore More

Humanity can't afford to wait, so neither can we.

Let's talk